Because that would be illegal to do if they are engaged in talks about a potential merger or sale, which they obviously are.

Right. Because it would make more sense to file for bankruptcy and have the assets forcibly liquidated at well below market value than to sell the company before that would become a necessity.

That's a direct pickup from the February 8 release. So nothing new.

If news of a sale isn't released by Monday or if the financials don't strongly hint at an imminent sale, you're probably right. But that'll only be because MMs will be taking advantage of the lack of news which will cause a few momo/speculative traders to exit. It won't be indicative of the end of TZYM, which you seem to think will be the case.

Yeah, I'd love to see it before ASCO in June.

Especially if a NASDAQ uplisting comes soon.

If YMI is any indication, the stock will get to the pps sale price immediately, so selling once that hits makes the most sense, in my opinion.

I'll buy after the reverse split, which will come shortly after DTC hold. Count on it.

LOL. Why assume 1000 shares is significant? Alert me when it's 100,000 dumped AH.

You're worried about a $500 AH sale? Really?

Probably not. More likely people playing the speculation of news of a sale being released prior to earnings. That being said, I won't be terribly surprised if the company is actually sold this week. It's going to happen at some point, in my opinion; it's just a matter of when.

Thinking there's a good chance TGTX will consolidate here before the next leg up. Current price is near the 50% fib retrace from last surge. I added more at this level.

This article is from September 2012. It provides nothing new.

I agree. New 52-week high is near.

Roth puts a PT of $13 on TGTX today. Still a steal at these prices.

http://www.streetinsider.com/New+Coverage/Roth+Capital+Starts+TG+Therapeutics+%28TGTX%29+at+Buy/8180641.html

Stockpickr article wasn't posted until the stock hit the $.28. The run started prior but was helped along by stockpickr.

Oops!

Bob Temple from the FDA hosted a conference about DMD today. Some gems from the conference, as spoken by Bob:

"Approval is not uncommon for trials with under 20 patients."

"Dystrophin is a pretty good candidate for a surrogate endpoint."

"A smaller than usual but excellent Phase 2 study can do the job."

"Many orphan drugs have been approved based on single-arm studies, especially where the effect is large."

I'm going to go out on a limb and say eteplirsen receives accelerate approval.

The news regarding the CBO's severance package tells me that you are right. I think it will be sooner rather than later.

Are you suggesting management shouldn't be blamed? Ultimately, investors' decisions are theirs and theirs alone, but this management is a group of snake-oil salesmen. Not sure how that could be argued at this point.

So did ANAC, just this week. Their results were less than stellar, and the stock took a big hit. I'm not saying CLSN's will be poor; I'm saying the timing and wording of the PR isn't to send secret signals to investors.

You are correct.

Pivotal is a neutral word--its connotation is neither positive or negative. It means "crucial", as in "crucial to the success or failure of a Phase 3 trial." Every Phase 3 trial is pivotal; not just those that succeed. By your logic, trials that fail shouldn't be considered pivotal, and that's incorrect.

I could just as easily argue that the HEAT trial has ended because they referred to it in past tense in the PR. But I'm not going to do that because that is trying to create a secret message where one doesn't exist.

Results are a complete toss up.

That is some seriously wishful thinking.

Yep. Today was a fantastic opportunity to enter at dirt cheap prices.

Go figure. Could be that most investors realize Eric and his unaudited financials are a load of bull?

This was a case of MMs (or some large holder) waiting for a negative news article to come out this close to the binary event. In my opinion, that article was simply the fuel that the MMs used to trigger a panic.

It was a matter of time before another negative article came out before results. The MMs were just ready to take advantage of it.

While I don't necessarily believe the author of the article was somehow involved in the drop, I also don't believe the article release and subsequent drop were coincidental.

I think this will move soon simply because it was oversold for so long. There will be a big pump, and I bet we'll hit $1 within a month or two, possibly much sooner. That's what I'm expecting anyway.

Well, despite my skepticism, I hope you're right.

I strongly disagree about the institutional accumulation. This is buying from biotech and penny stock players. OTC stocks receive virtually no institutional investment, and that isn't going to change here simply because people want to believe it is happening. You'll see institutions purchase after a) an FDA approval and/or b) a NASDAQ listing.

I'm not trying to butt heads with you, but this is how it works. Find me a few OTC stocks with high institutional investment (not ones that were formerly NASDAQ stocks and recently delisted--ones that have been OTC for years). I highly doubt you can because it just doesn't happen. The odds heavily show it isn't happening here.

I'm a long and have been invested since the low $1's, but I am also realistic.

Agree 100%

No big deal on diluting the amount of shares by 25%?! Sure, man, keep thinking that. The market is going to disagree with you. You'll see the share price drop sharply at some point in the next few weeks, and the warrants will be the reason why. I'll be selling before then, and then repurchasing after people panic. This stock will ultimately be fine after the warrants are exercised and the price has found a bottom, thanks to the AdCom and PDUFA, but between now and the AdCom, there will be a significant sell off because of the warrants. Bank on it.

FDA issues draft guidance on abuse-deterrent opioids

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm334785.htm

This could be good news for TTNP potentially, if anything because they have an opioid drug up for review. Per Twitter:

Adam Feuerstein ?@adamfeuerstein
FDA holding media briefing at 3 pm on draft guidance on developing new formulations of opioid drugs with abuse deterrent properties

Doubtful. This is $heff and other bio runup players getting on board. (I'm not complaining because I bought in before they did.)

$10 isn't going to happen before FDA approval. That's nothing but mindless pumping without looking at the facts and history of this stock. The company has nearly 20 million shares of options and warrants below $2.13 (most of which are at $1.25) that will be on the market soon. That will increase the share count by 25%. $2.50 to $3 is far more realistic pre-FDA approval. $4 later in the year if the company gets a NASDAQ listing.

And yes, I have many shares in this company which I am still holding, but I won't be holding them until they reach $10 because that ain't happening anytime soon if at all.

Yeah, got in that one in the $0.50s. Should easily hit a $1 before its PDUFA at the end of March. Quite possibly $2. Lots of significant institutional investors and insiders, including Baker Bros and Tang.

Alerted at $0.86. Now trading at $1.07 two trading days later. Still think there is room to run.

Not currently. Thought about getting into AMBS when it was only 4 cents, but decided not to. Investment fail.

I'm keeping my eyes on PTN. They have a huge Phase 3 that should start up in a year or so for female sexual dysfunction (Phase 2 results were very, very good), but in the meantime, the share price may drop to the $.20's. Only problem is a potential reverse split though, so if it does drop that low, gotta see how much cash they have before taking the gamble.

CRMD is about to make a huge run. Only 9 million shares in the float.

Unless briefing docs are very positive, that's unlikely. More often than not, the share price drops upon the release of briefing docs. The sole purpose of the documents is to address any concerns with the drug, so investors typically see such things as a negative, even if they shouldn't. In the case of Ampligen, it's a really tough call at this point on whether or not the AdCom will recommend it. Its history does not lend itself to that, but the patient advocacy and FDASIA may outweigh that.